I had already discussed the stock U.C.A. Aktiengesellschaft here ☛ https://ppinvest007.substack.com/p/from-searching-to-being-found-uca?r=dnjysA lot has happened since then!The starting point: A silent giant in the micro-cap universeIn order to understand the implications of the current situation in all its depth, we must first take an analytical look at the protagonists. The U.C.A. Aktiengesellschaft, listed on the over-the-counter market under the ISIN: DE000A12UK57, is not a loud, shrill venture capital booth that throws buzzwords around at hip conferences. Historically, it has been an extremely conservatively managed private equity and venture capital company. The business model is based on providing equity capital to medium-sized companies, whether through early-stage investments, growth financing or management buy-outs.For many years, the management team has demonstrated an extremely fine, almost uncanny nose for niche topics that generate stable cash flows or become dominant market leaders in their respective segments. But the real game changer that has catapulted the U.C.A. from its tranquil existence as an illiquid micro-cap – with a free float of just around 29.15 percent – into the bright spotlight of professional value investors bears the name Pflegia.Until recently, Pflegia was the absolute crown jewel in the U.C.A. portfolio. A majority stake that not only solves an urgent social challenge, but also scales incredibly profitably in the process. When a company experiences such a massive, fundamental increase in value, the investor inevitably faces the question at some point: hold on and hope or cash in? The U.C.A. has opted for a third, far more intelligent path, which we will examine in detail.The fascinating thing about the current situation is the blatant inefficiency of the market. In a highly efficient market, such as the one we see in DAX or S&P 500 stocks, an ad hoc announcement of such an inflow of liquidity would raise the price to net asset value (NAV) within fractions of a second by high-frequency traders. However, for companies with low free float, minimal trading volumes on exchanges such as Lang & Schwarz, and a complete lack of analyst coverage, this pricing process often takes months, if not years. It is precisely in this time lag that the arbitrage opportunity lies for the informed, patient private investor. The U.C.A. is a prime example of the fact that markets are not perfect on a small scale.Thanks for reading! Subscribe for free to receive new posts and support my work.The Care Miracle: How to Monetize the Care CrisisLet’s dive deep into the mechanics of Pflegia, because this is where the rain of money comes from. Founded in 2019 by Lennart Steuer, Felix Westphal and Masoud Shahryari, the company set out to repair one of Europe’s most dysfunctional and painful labour markets: the health and care sector.Hospitals, clinics and nursing homes have been suffering from a chronic, structural shortage of staff for years. Historically, these institutions have resorted to expensive temporary employment agencies or classic headhunters to fill vacancies. These intermediaries demanded horrendous hourly surcharges for temporary workers, while the nurses burned out and often resigned themselves to unattractive shift work. Traditional job boards also didn’t work, as they only generated a flood of unqualified or poorly matching applications.Pflegia’s strategic stroke of genius was the consistent introduction of an AI-supported, data-driven “reverse recruiting” model. The platform simply reversed the established power dynamics. Instead of the already stressed nurse rummaging through irrelevant job advertisements, the clinic applies to the nurse.The process is elegant and smooth: candidates create a structured, digital profile in five simple steps. They indicate their certified competencies, specializations, geographical boundaries, preferred shift models and, of course, their salary expectations. When this anonymous profile is complete, Pflegia’s proprietary matching engine takes over. The algorithm compares these data points with the vacancies of the verified healthcare facilities and assigns compatibility scores. Employers can then send targeted offers to nursing staff. The candidates decide autonomously who they want to meet.The decisive competitive advantage that distinguishes Pflegia from classic temporary work (temporary work) is the focus on direct, permanent positions. Pflegia only charges employers a fee when a position is successfully filled, and demonstrates its confidence in long-term relationships through a reimbursement guarantee in the event that the caregiver leaves the company during the probationary period.With this superior architecture, Pflegia built enormous two-sided network effects. By mid-2026, the proprietary database had grown to over 900,000 registered caregivers, supported by partnerships with more than 10,000 caregivers nationwide. Pflegia quickly became the undisputed top dog in the German-speaking world.The financial result of this technological dominance is breathtaking. Based on the key financial figures for the calendar year 2025, Pflegia generated sales of a whopping 30.0 million euros and an operating result (EBITDA) of 7.0 million euros. This corresponds to an impressive operating EBITDA margin of around 23.3 percent with robust revenue growth of 25 percent year-on-year.These outstanding unit economics naturally aroused covetousness in the high-finance world. In a highly structured sales process led by the investment bank Raymond James, which started at the end of 2025 with the first non-binding offers (NBOs), a global heavyweight finally joins the company. The French private equity giant Ardian struck via its dedicated growth strategy and acquired the majority stake in Pflegia. This leveraged growth buyout was financed by senior credit facilities from the debt fund Artemid. On July 9, 2026, U.C.A. AG announced the official closing of the transaction.The sale of Pflegia to Ardian is an academic lesson in successful venture capital. A real, urgent problem with enormous suffering on the customer side is solved by a scalable technological platform. This leads to extreme margins, strong network effects and ultimately to massive premium valuations at exit. The fact that a globally active sponsor like Ardian is getting involved here underlines the institutional quality of the asset. For the U.C.A., this means the end of the risky construction phase and the glorious entry into the harvest season.The “Second Bite at the Apple”: Why 18.5 percent is better than 100 percentNow it’s getting extremely clever from a structuring point of view. If the U.C.A. had sold its entire shares (previously it held over 57 percent as the majority owner), we would have seen a clean, complete exit. The money would be in the account, the Pflegia chapter would be closed for good. However, in classic private equity transactions of this caliber, the seller is often offered a so-called “rollover” – a reinvestment in the new buyer structure.U.C.A. has exercised this option and retains around 18.5 percent as a minority stake in Pflegia. Why is this strategic move so essential? Because Ardian didn’t buy the company to put it on the shelf as a trophy and milk dividends. Ardian’s growth fund pursues the aggressive goal of scaling profitable technology companies and expanding across borders. The plan is to build Pflegia from an all-German market leader into an integrated, pan-European digital talent platform for healthcare.With Ardian’s huge capital, M&A expertise and international network behind it, Pflegia is poised for the next, even more gigantic phase of growth. The three founders, Lennart Steuer, Felix Westphal and Masoud Shahryari, will remain on board and retain their operational management roles as well as significant own shares, perfecting the alignment of interests.“The remaining 18.5% stake will transform U.C.A. from a direct operating value driver into a highly attractive financial investment that can act as a lever on the future valuation of U.C.A. AG without tying up its own liquidity.”This assessment from the available analyses hits the nail on the head. If Ardian resells Pflegia to an even larger strategic buyer or via an initial public offering (IPO) in a typical four to seven years (the classic PE holding cycle), the company’s valuation is expected to be many times what it is today. The U.C.A. will then participate in this increase in value again with its 18.5 percent and completely without any operational action of its own. This is the proverbial “Second Bite at the Apple”.While Pflegia is expected to retain all profits (retention) in this expansion phase to finance growth, the U.C.A. no longer bears the entrepreneurial risk and massive capital requirements. The role changes from the responsible majority owner to the comfortable, strategic co-investor.This move is the financial definition of “eat the cake and still keep it”. It realizes an immense cash gain in the mid-double-digit million range, which ensures the survival and payability of the holding company for decades, but at the same time retains the asymmetrical upside opportunity of a real tech rocket. The risk of loss of the remaining 18.5 percent is cushioned mentally and balance sheet by the massive cash return that has already been realized, but the chance of profit is theoretically completely open.The HGB secret: hidden reserves as the value investor’s best friendIf you, as a modern investor, run the balance sheets of U.C.A. AG through a standardized screener, you will probably stumble across an accounting circumstance that is confusing for many international algorithms, but a source of constant joy for cunning German value investors: the German Commercial Code (HGB).The U.C.A. does not balance its financial statements in accordance with international IFRS standards. IFRS would require that financial assets be regularly remeasured at their current fair value. The German HGB, on the other hand, is extremely protective of creditors and conservative. It knows the strict acquisition value principle and the imparity principle. In concrete terms, this means a fascinating effect for our remaining stake in Pflegia: With the contractual disposal of the majority, the position in the U.C.A. balance sheet moves to the classic financial investments. Their value is poured into concrete and “frozen” at the historical acquisition cost of the re-investment, so to speak.No matter how fantastically Pflegia develops in the hands of Ardian in the next 36 months, no matter whether the value of the company explodes through clever acquisitions in France or Scandinavia – there will be absolutely nothing to be seen in the audited HGB balance sheet of the U.C.A. According to the strict HGB realisation principle, future fundamental increases in value may only be reported as profit in the income statement (P&L) if the shares are actually sold at the final secondary sale.The balance sheet of the U.C.A. will “lie” structurally and completely legally in the coming years – and massively downwards. This effect builds up enormous hidden reserves. In the foreseeable future, the reported book value will be drastically below the true economic value (net asset value) of the investment. For automated screeners and superficial analysts, the stock looks visually more expensive than it is in reality, as equity is reported too low. For the deep-digging, thinking investor, on the other hand, this is an official invitation to acquire a hidden treasure before the market is forced to realize it in hard currency on future exits. It’s the perfect hide-and-seek game for clever allocators.Cash Cow MedLearning: The Invisible, Reliable Fortress in the BackgroundDue to the media hype about the exit, one could easily fall into the mistaken belief that the U.C.A. is a classic “one-trick pony”, a company that exists exclusively through the singular Pflegia stroke of luck. That would be a fatally wrong assumption. Let’s take an analytical look at the company’s current operational “cash cow”, which often flies completely under the radar: MedLearning AG, in which the U.C.A. holds a remarkable 78.00 percent of the shares.The business model of MedLearning, in which the U.C.A. has been on board since 2009, is as incredibly reliable as Swiss clockwork. Through its renowned portal cme.medlearning.de, the company acts as one of the leading providers of online medical training in Germany. In Germany (as in many other Western health care systems), established and clinical doctors are strictly obliged by law to undergo continuous training. They must collect so-called CME (Continuing Medical Education) points at regular intervals in order not to jeopardize their approval.MedLearning provides the digital platform for exactly this purpose. Monetization is not done by the doctor, but extremely lucrative in the B2B sector. The training modules are usually sponsored by the pharmaceutical industry or medical technology companies, which communicate their latest scientific findings to the medical profession in this way.This model generates highly reliable, recurring revenues and extremely stable operating cash flows. Through an existing profit transfer agreement, around one million euros in pure profit flow directly into the coffers of the U.C.A. every year. In addition, MedLearning has not stood still technologically. The company is now making targeted use of artificial intelligence (AI) solutions to make the platform, administration and, above all, expensive content generation massively more efficient.MedLearning is the fundamental, rock-solid ground on which the U.C.A. house stands. With a market capitalization of the holding company of around 44 to 48 million euros and a secure, recurring profit contribution of around 1 million euros, this investment alone offers a massive safety net. If we apply a price-earnings ratio (P/E) of 12 to 15, which is conservative for this crisis-proof segment, this results in an enterprise value of 12 to 15 million euros for MedLearning alone.MedLearning finances the ongoing operations of the holding company almost single-handedly. This has an invaluable strategic advantage: the immense exit proceeds from other projects (such as the sale of Pflegia) do not have to be nibbled at to cover administrative costs (overhead). They can be used for new strategic initiatives, acquisitions or massive dividends without any time pressure. It’s the perfect, invisible foundation for a long-term dividend machine.The broadly diversified remaining portfolioEven apart from the dominance of Pflegia and the reliability of MedLearning, U.C.A. has built up a multifaceted, highly interesting portfolio of smaller minority holdings and co-investments over the years. This “residual portfolio” is often set at a value of zero in superficial valuations, but on closer inspection it offers potential.The management often invests directly, but sometimes also indirectly via vehicles such as Upside Co-Invest 2019 GmbH or through investments in funds (e.g. Index Growth V) in more mature companies.In addition to these more mature investments, the U.C.A. operates a classic “Global Brands Portfolio”, consisting of around 20 international blue-chip stocks and ETFs for liquidity management. However, the latest initiative is far more exciting: Since the end of 2022, the U.C.A. has been specifically participating in very early financing rounds (so-called pre-seed and seed financing).Corporate Governance and the Strategic Relocation: Why Grünwald?Before we get to the all-important question of future capital allocation, it is worth taking a brief look at the structure and management of the company. U.C.A. AG is managed by a lean, experienced Executive Board. As a graduate in business administration, Dr. Jürgen Steuer steers the company’s fortunes operationally.Two details are particularly revealing for analysts. First, insider transactions. In mid-2023 (and early 2025), there were minor restructuring by the Management Board member Dr. Jürgen Steuer as well as closely related persons (such as K.F.P. GmbH & Co. KG), which is part of normal liquidity management for family- or founder-led investment companies, but is always an indicator of the close ties of the management to the share.Secondly, and this is the far more interesting aspect, the U.C.A. recently gave up its venerable headquarters in Munich’s Stefan-George-Ring. The move took place in the directly adjacent, famous Grünwald. In investor forums such as wallstreet:online, this step was attentively registered and aptly commented: “The assessment rate of the trade tax looks friendlier”.And that’s exactly the point. Grünwald is notorious in Germany for its extremely low trade tax rate compared to the expensive state capital of Munich. For an investment company that is on the verge of realizing a capital gain in the mid-double-digit million range, this move is a strategic masterstroke of tax optimization. It shows that the management not only has a knack for good investments, but also masters the keyboard of business cost optimization down to the last detail. Every euro saved in trade tax is one euro more, which can be distributed to shareholders as a dividend in the future.The 50 million euro crucial question: What happens to the cash?We come to the absolutely critical point of the entire analysis, the linchpin for the short- to medium-term share price development. On July 9, 2026, U.C.A. received a “net cash inflow in the mid-double-digit million range” through the official closing of the Pflegia deal. In well-informed financial circles and based on Pflegia’s rumoured company values, this amount is estimated at around 40 to 50 million euros.To better understand the dimension: The total market capitalization of the U.C.A. in July 2026 was also in this range (approx. 44 to 46 million euros) at a share price of around 71 euros. The company now de facto consists almost exclusively of pure cash on the balance sheet, based on the current market capitalization.The crucial, all-dominating question now is: How will management allocate this huge capital? Based on the structural data (approx. 623,281 circulating dividend-bearing shares after deduction of approx. 38,700 treasury shares), four probable future scenarios can be outlined:Scenario 1: The massive special dividend (probability: high, approx. 70%) This is the variant that investor dreams are made of. With an inflow of 40 million euros, for example, around 64 euros per share in liquid funds would be freely available in purely mathematical terms. U.C.A. has traditionally been extremely shareholder-friendly. Just recently, on July 2, 2026, a dividend of 4.70 euros per share (from the 2025 retained profit of just under 3 million euros) was distributed.A large part of Pflegia’s proceeds is likely to be proposed as a special dividend as part of the annual figures for 2026 (expected in spring 2027) and distributed after the Annual General Meeting in May/June 2027. It fundamentally contradicts the economic DNA of the U.C.A. to let such a “cash mountain” sit on the balance sheet unused and, in the current interest rate environment, possibly with negative interest rates in real terms. The return to the shareholders is the logical, value-generating consequence.Scenario 2: Re-investment & establishment of new portfolio companies (probability: very high, approx. 80%) This scenario will almost certainly occur in combination with scenario 1. U.C.A.’s very own core business is investing, building up and selling companies. Since the Pflegia exit is now missing a massive revenue and value driver in the operating portfolio, the management will have to retain part of the liquid funds (expected to be 10 to 15 million euros). This capital will be used continuously from the third quarter of 2026 onwards to build up new majority or significant minority shareholdings in the core competencies of HR tech, software or digital health.Scenario 3: Share buyback program (probability: medium, approx. 30%) On the academic paper, a share buyback would make a lot of sense at the current valuation. It’s a tax-efficient way to return capital to investors and would massively increase the intrinsic value of the remaining shares by buying below the NAV. But in practice, there is a fundamental catch: the liquidity of the stock on the stock exchange. The free float of 29.15% is already tiny. A large-scale buyback program would completely dry up trading in the stock on stock exchanges such as Lang & Schwarz. If at all, this instrument will only be used homeopathically (up to a maximum of 10% of the share capital) as a supplementary measure to cushion temporary price weaknesses.Scenario 4: Growth financing of existing investments (probability: medium to high, approx. 60%) Parts of the fresh money could be used intelligently to massively accelerate the growth of the remaining cash cows such as MedLearning AG through targeted capital increases or shareholder loans. Investments in even deeper AI integrations for content creation or a classic buy-and-build strategy in which smaller competitors in the CME market are taken over and integrated would be conceivable here.It is obvious that we will see a “hybrid solution”. In the coming quarters, the U.C.A. will channel a noticeable amount into new, promising companies of the future in order to keep the engine of its business model running. At the same time, however, it will present loyal shareholders with a historic, substantial special dividend in spring 2027. Already today, some informed investors are trying to anticipate this fantasy in the price, which drove the value above the 70 euro mark in the summer of 2026 (in some cases with ask prices at 72.50 euros to 87.00 euros on tight trading days). Nevertheless, the broad market consistently underestimates the sheer mathematical force of this imminent distribution. If you buy today at around 71 euros, you could in the best case get back an enormous part of your investment within a year through the dividend after tax alone.The Naked Truth of Mathematics: The NAV CalculationAll the fine words about strategic visions, clever HGB balance sheets and a tax-saving move to Grünwald ultimately pale in front of the cold, hard and incorruptible mathematics. What is U.C.A. AG really worth on the stock market today?The calculation of the so-called net asset value (NAV), i.e. the substantial net asset value per share, is the only serious and meaningful valuation benchmark for an investment company. Let’s start from the known, verifiable structural data: The current market capitalization is around 44 to 48 million euros at a price of around 71 euros. After deduction of the treasury shares held in the portfolio, exactly around 623,281 shares in circulation that are entitled to dividends remain.A customary, conservative sum-of-the-parts (SOTP) estimate immediately after the closing of the Pflegia deal in July 2026 is as follows:Conclusion on the valuation: At a current stock market price of a good 71 euros, the U.C.A. share is quoted at an almost high discount to its intrinsic value. The market has taken note of the enormous inflow of liquidity from the Pflegia deal in the form of a press release, but has not yet fully priced it into the price.Thanks for reading! This post is public so feel free to share it.ShareWhat do you think about the stock? My stock ideas are part of the“Elite Investor Feed” at ☛ Yellobrickthe performance of my stock ideas is tracked, independently of me. At the moment, it looks like this.“Speculative investments are like a tennis match: the decisive factor is to concentrate fully on the next ace instead of being annoyed by the last double fault.” A. GerstenbergerDisclaimerThis text was partly created with AI applications.All content is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell securities or other financial market instruments. Of course, I try to present the facts to the best of my knowledge and belief, but they can still be false in whole or in part.Therefore, I do not accept any liability for investment decisions that you make on the basis of the information presented here.Conflict of interest: At the time of publication, the author of this publication holds shares/securities of the securities/companies discussed here and intends to sell them depending on the market situation and could benefit in particular from increased trading liquidity. As a result, there is a concrete and clear conflict of interest.